Business
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that existing Lucentis patients can be safely transitioned to CIMERLI - - Dedicated retina sales team and CIMERLI Solutions™ patient services hub will ensure successful access and reimbursement - REDWOOD CITY, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all approved indications. CIMERLI is an anti-VEGF therapy within a class of biologics that has been revolutionary in helping retinal patients maintain or gain vision. CIMERLI was approved by the U.S. Food and Drug Administration (FDA) in August 2022, having met FDA’s standards of biosimilarity and interchangeability to the reference product, including safety, efficacy and quality.1 \"With the upcoming launch of CIMERLI, retina specialists, patients and payors can expect the same efficacy and safety as Lucentis delivered with the comprehensive savings and patient support services that Coherus is known to deliver,\" said Paul Reider, Chief Commercial Officer of Coherus BioSciences. “We look forward to competing in this large and growing market with our dedicated and experienced retina sales team, leveraging our proven commercial expertise as we accelerate adoption of CIMERLI over the coming months.” “A biosimilar that is interchangeable with Lucentis will enable my patients greater treatment access and choice,\" said David M. Brown MD, FACS, Director of Clinical Research, Retina Consultants of Texas. \"With the same five FDA-approved indications, clinical equivalence to Lucentis in terms of efficacy and safety, and the same dosage strengths, I believe that CIMERLI will address biologic treatment costs without compromising safety and clinical outcomes.\" “Coherus has both the opportunity and the capability to be very successful with the CIMERLI launch, as we start the next leg of our revenue inflection towards our target range of $1.2B to $2.2B in 2026,” Denny Lan...